Staurosporine

製品コードS1421 別名:CGP 41251

Staurosporine化学構造

分子量(MW):466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

サイズ 価格(税別)  
JPY 44820.00

カスタマーフィードバック(3)

  • Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

製品安全説明書

PKC阻害剤の選択性比較

生物活性

製品説明 Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
ターゲット
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
体外試験

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MlvTR5l1d3SxeHnjxsBie3OjeR?= M330UVQ5KGh? NF3XRnNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OIUuODZizszNMi=> M3L1TFIyOzh6MUmx
human colon cancer cell line (LoVo cells) MlfxVJJwdGmoZYLheIlwdiCjc4PhfS=> MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKGOxbH;uJINidmOncjDj[YxtKGyrbnWgLGxwXm9iY3XscJMqKHW|aX7nJG1VXCCjc4PhfUwhUUN3ME2wMlAxOSEQvF2u MXyxNVU6OTVyNR?=
human LoVo cells M1zGNHBzd2yrZnXyZZRqd25iYYPzZZk> NELZWVk1QCC2bzC3NkBp MnHSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb2\vJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZk> MlvRNlIyQDJ7Mkm=
P19 cells NIrnfYNHfW6ldHnvckBie3OjeR?= MmXETY5pcWKrdHnvckBw\iCSbHH0[YxmfC2mZYLpeoVlKGe{b4f0bEBn[WO2b4KgdoVk\XC2b4KgbY4hWDF7IHPlcIx{NCCLQ{WwQVAvODB{IN88UU4> NH;h[JYyPTd5MUSxPS=>
human BJ cells NFfKRYVEgXSxdH;4bYPDqGG|c3H5 NVzzXI8{PzJiaB?= MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3HsZ4VqdiCDTTDhd5NigSxiSVO1NF0xNjByMjFOwG0v MmHUNlI6OjFyOEG=
human HT-29 cells M4XJTmZ2dmO2aX;uJIF{e2G7 MVeyJIg> MW\F[oZm[3Rib36gcYl1d2Oqb37kdolidCCvZX3idoFv\SCyb4TlcpRq[WxiaX6gbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiMjDodpMhfXOrbnegTmMuOSC|dHHpcolv\yCkeTDmcJVwemW|Y3XuZ4Uh[XO|YYm= MnfTNlE1Ojh|N{W=
human A549 cells MnjYR5l1d3SxeHnjxsBie3OjeR?= NHPFVFc4OiCq NHTKcXNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJI1mfGixZB?= NUTxOW44OTh2OES3O|U>
human HT-29 cells M1j5[WZ2dmO2aX;uJIF{e2G7 MmjiTY5pcWKrdHnvckBw\iCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJJBwfGWwdHnhcEBqdiCqdX3hckBJXC1{OTDj[YxteyC3c3nu[{BLSzFiZInlJJN1[WmwaX7nJIJ6KG[udX;y[ZNk\W6lZTDwcIF1\SC{ZXHk[ZIh[XO|YYmsJGlEPTB;Mj61JI5O NX7WeVkzOjF3MUOyPVM>
human HT-29 cells NIG5O3VHfW6ldHnvckBie3OjeR?= NWfI[YpFOiCq M360OWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSGStNlkh[2WubIOgZZN{\XO|ZXSgdoVlfWO2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIFnfGW{IEKgbJJ{KGK7IIXzbY5oKEqFMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViY3XscE1j[XOnZDDhd5NigSxiRVO1NF0zNjZibl2u M1LVSVIyQTd|MUCx
Sf9 cells Mn\wSpVv[3Srb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJHN6cyCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzMEBKSzVyPUOgcm0v NGHue4MyQDh{M{e4OC=>
human HUVEC Mo\DVJJwdGmoZYLheIlwdiCjc4PhfS=> Mmr1OFghfG9iN{KgbC=> NF\Rfo1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjVWmVEKGGodHXyJFQ5KHSxIEeyJIhzeyCkeTDNWHQh[XO|YYm= MViyNlE5Ojl{OR?=
P19 cells M3zmSWZ2dmO2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKFC{b4TlbY4hU2mwYYPlJGEhcW5iUEG5JINmdGy|LDDJR|UxRTRibl2u M4\4bFE2PzdzNEG5
Sf9 cells M4DJUGZ2dmO2aX;uJIF{e2G7 NInnT2tKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFEhdWmwIHL5JGVNUVODIHnuJJBz\XOnbnPlJI9nKDFidX3vcE9NKEGWUB?= MkTtNVc{OTV6NUO=
Sf21 cells M1rYSWZ2dmO2aX;uJIF{e2G7 NHPETGdKdmirYnn0bY9vKG:oIFrBT|Mh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOsJGlEPTB;NjDuUU4> NUjiTotjOTdyOEiwOVk>
human colon carcinoma cell line HCT116 MnPJSpVv[3Srb36gZZN{[Xl? NYHmb2JQS2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MXuxOVU{PzN2NR?=
human ST486 cells MoP6VJJwdGmoZYLheIlwdiCjc4PhfS=> MWG0PEB1dyB5MjDo NFL1bY1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPUOFg3KGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PyCwTT6= M1;TXlIzOTh{OUK5
human MDA-MB-231 cells MlWwR5l1d3SxeHnjxsBie3OjeR?= M4fWU|czKGh? NGPJS4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\CxiR1m1NF04NjFibl2u NULFVZgyOTh2OES3O|U>
P19 cells NYG0dWVlTnWwY4Tpc44h[XO|YYm= MlrQTY5pcWKrdHnvckBw\iCFeXPsbY4u\GWyZX7k[Y51KGurbnHz[UAyKGmwIGCxPUBk\WyuczygTWM2OD16IH7NMi=> M3PZWFE2PzdzNEG5
human DLD1 cells NUT1RZQ2WHKxbHnm[ZJifGmxbjDhd5NigQ>? MmLaOFguPzJiaB?= MlfCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGTFSxJINmdGy|IHHmeIVzKDR6IITvJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9PUBvVS5? M17zNFIzOTh{OUK5
insect cells MUnGeY5kfGmxbjDhd5NigQ>? M{C1S2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUHntNUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzJIJ6KEiWUl[sJGlEPTB;MUCgcm0v NHfmb3UyQTF5OUC3Oi=>
V79 MZ cells NYXhbYlRTnWwY4Tpc44h[XO|YYm= NVvDO2cyUW6qaXLpeIlwdiCxZjDoeY1idiCjbHTvd5Rmem:wZTDzfY51cGG|ZTDlfJBz\XO|ZXSgbY4hXjd7IF3aJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzkc5N1\XKxbnWgd5lvfGinc3nzMEBKSzVyPUGxJI5ONg>? NF3RS3AzPDR{MkWxPS=>
P19 cells NH3LfpdHfW6ldHnvckBie3OjeR?= Mmq1TY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKGmwIGCxPUBk\WyuczygTWM2OD1zNDDuUU4> M2jQ[lE2PzdzNEG5
Sf9 cells M4C3VmZ2dmO2aX;uJIF{e2G7 MXSyNEBucW6| MlfRTY5pcWKrdHnvckBw\iCqdX3hckBHgW5iZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCyNEBucW6|IHL5JGVNUVODIHnuJJBz\XOnbnPlJI9nKDFidX3vcE9NKEGWUDygTWM2OD1zNTDuUU4> NV7qTFRSOTd|MUW4OVM>
human PBMC Mn:ySpVv[3Srb36gZZN{[Xl? Mnf3NlQhcA>? MnHFV5VxeHKnc4Ppc44hd2ZiSVyyJJBzd2S3Y4Tpc44hcW5iaIXtZY4hWEKPQzDh[pRmeiB{NDDodpMh[nliRVzJV2EtKEmFNUC9NVYhdk1w MWWxPFU5PTB2Nh?=
human A549 cells M4DUeGN6fG:2b4jpZ:Kh[XO|YYm= MXS0PEBp NEHKS|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhNCCLQ{WwQVIxKG6PLh?= NHTTNVgzPTh{NUmzOC=>
human CEM cells MUDDfZRwfG:6aXRCpIF{e2G7 MkXjO|IhcA>? MoD4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTJ|IH7NMi=> MnrsNlI6OjFyOEG=
human HeLa cells MWnDfZRwfG:6aXRCpIF{e2G7 MVq0PEBp NHflZ2REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NlUhdk1w NFXUd4UzPTh{NUmzOC=>
human PC3 cells M3z4WGN6fG:2b4jpZ:Kh[XO|YYm= M33iVlQ5KGh? NGjGZZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUAtKEmFNUC9N|Ehdk1w M4TsNlI2QDJ3OUO0
human SF268 cells MoLRR5l1d3SxeHnjxsBie3OjeR?= MVS0PEBp NH\zdYhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVQ1KG6PLh?= MorQNlE2OTN{OUS=
human MCF7 cells MkHuR5l1d3SxeHnjxsBie3OjeR?= MmnHOFghcA>? NGLMXHdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVAhdk1w NVvq[JFNOjF|OEixPVE>
HEK293 cells MnPmR5l1d3SxeHnjxsBie3OjeR?= Mmi5O|IhcA>? M3r3SmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{R3zvJIF{e2G7LDDJR|UxRTV4IH7NMi=> MX:yOFc3OzJ4Mh?=
HUE cells NGfTRnBHfW6ldHnvckBie3OjeR?= NYHTNGh7QTBibXnudy=> Mm\sTY5pcWKrdHnvckBw\iCYRVfGVlIhcW5iSGXFJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiVlXHSk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hfHKnYYTl[EBnd3JiOUCgcYlveyCkZX\vdoUhXkWJRjDjbIFtdGWwZ3WgZpkhTUyLU1GsJGlEPTB;N{Cgcm0v MkHnNlAyPzBzNkO=
human A431 cells MWjDfZRwfG:6aXRCpIF{e2G7 MXyyOEAhcA>? NFfBeWlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFI1KGi{czD1d4lv\yCDbn7lfIlvKF[nRlnUR{9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KE2WVDDhd5NigSxiSVO1NF04OCCwTT6= MoX1NlI2PDFyNUG=
human Jurkat cells NHTzc3VRem:uaX\ldoF1cW:wIHHzd4F6 MofpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDKRWs{KGW6cILld5NqdmdiSVyyMZN1cW23bHH0[YQhcHWvYX6gTpVzc2G2IHPlcIx{NCCLQ{WwQVcyKG6PLh?= M1jwdVE6PDJ5MkCz
HEK293 cells MULGeY5kfGmxbjDhd5NigQ>? NUPyXJdzUW6qaXLpeIlwdiCxZjDJUE05KHKnbHXhd4Uh[nliSFXLNlk{KGOnbHzzJIV5eHKnc4PpcochWEuFLXLleIEzNCCLQ{WwQVc4KG6PLh?= M1\ONlE2PzdzNEG5
human KE-97 cells MV3DfZRwfG:6aXRCpIF{e2G7 M{LiXVczKGh? NXPlPWNDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0VvOUegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRz\S2JbH:gcJVucW6nc3PlcpQh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMzFOwG0v MUOyOFMzQDJ6Mx?=
human CHOK1 cells MVjDfZRwfG:6aXRCpIF{e2G7 M{fvbVQ5KGh? NGHmWFVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEUE:NMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5zMzFOwG0v NVq0NnlWOjF3MUOyPVQ>
mouse NIH/3T3 cells NH;mcXdEgXSxdH;4bYPDqGG|c3H5 MUC5OkBp M3P4eWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9|VEOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjJizszNMi=> MY[yOFM3OTV{MR?=
human A2780 cells M{LQTWN6fG:2b4jpZ:Kh[XO|YYm= MV25OkBp Ml\aR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlIh|ryPLh?= MofaNlQ{PjF3MkG=
human 8505C cells MYrDfZRwfG:6aXRCpIF{e2G7 NGPNeWQ6PiCq M1jDZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFg2ODWFIHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE4zKM7:TT6= MnGxNlQ{PjF3MkG=
human 518A2 cells M17WemN6fG:2b4jpZ:Kh[XO|YYm= NXrtd2lmQTZiaB?= NGLTRWJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA2OTiDMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F697zOIFnDOVA:OC5{IN88UU4> MkLENlQ{PjF3MkG=
human HuH7 cells NV;zRnFrS3m2b4TvfIlkyqCjc4PhfS=> MkTsO|IhcA>? MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2cnWtS4xwKGy3bXnu[ZNk\W62IHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlMh|ryPLh?= NYLrVFlLOjR|MkiyPFM>
FL5.12-Akt1 cells NXLNUoh6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NG\LdItCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZNPS5zMj3Bb5QyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjJ7IN88UU4> MlnqNVY1ODN4Mk[=
human MiaPaCa-2 cells MUTQdo9tcW[ncnH0bY9vKGG|c3H5 MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6= NXLUSZFuOTZ2MUO3PFA>
human BGC823 cells NHu0[ZVEgXSxdH;4bYPDqGG|c3H5 M2nPcFczKGh? M1;rSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> MUmyOFMzQDJ6Mx?=
human MCF7 cells MV;DfZRwfG:6aXRCpIF{e2G7 NV7C[WVVQTZiaB?= NG\XSItEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TT6= NVrFWodHOjR|NkG1NlE>
human A549 cells MU\DfZRwfG:6aXRCpIF{e2G7 MUe5OkBp MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;MD62JO69VS5? MW[yOFM3OTV{MR?=
HEK293 cells M3rwcmN6fG:2b4jpZ:Kh[XO|YYm= Moi3R5l1d3SxeHnjbZR6KGGpYXnud5QhUEWNMkmzJINmdGy|LDDFR|UxRTJizszNMi=> M{W4[FI2OzF4M{G3
human Raji cells  MWjDfZRwfG:6aXRCpIF{e2G7 NXr5WlRtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWmGsaTDj[YxteyxiRVO1NF0zKM7:TT6= MnjpNlU{OTZ|MUe=
human HepG2 cells NVLUTnVZS3m2b4TvfIlkyqCjc4PhfS=> Mni1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMtKEWFNUC9NkDPxE1w NUnHTmJpOjV|MU[zNVc>
human BJ cells NHS4cXNEgXSxdH;4bYPDqGG|c3H5 MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCTkBk\WyuczygSWM2OD1{IN88UU4> NH;NfHIzPTNzNkOxOy=>
human U937 cells MlPoR5l1d3SxeHnjxsBie3OjeR?= NF;1cXBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{NCCLQ{WwQVIh|ryPLh?= NFzVZXIyPzB6OEC2Oy=>

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
細胞試験:

[3]

+ 展開
  • 細胞株: PC12
  • 濃度: Dissolved in DMSO, final concentration 1 μM
  • 反応時間: ~32 hours
  • 実験の流れ:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (参考用のみ)
動物試験:

[8]

+ 展開
  • 動物モデル: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • 製剤: Dissolved in DMSO, and diluted in saline
  • 投薬量: ~10 ng
  • 投与方法: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 466.53
化学式

C28H26N4O3

CAS No. 62996-74-1
保管
in solvent
別名 CGP 41251

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00031681 Completed Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Estrogen Receptor-negative Breast Cancer|Extensive Stage Small Cell Lung Cancer|Gastrointestinal Stromal Tumor|HER2-negative Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Ovarian Sarcoma|Ovarian Stromal Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Cell Lung Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Triple-negative Breast Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Unspecified Adult Solid Tumor Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary National Cancer Institute (NCI)|Washington University Siteman Cancer Center December 2001 Phase 1
NCT00012194 Terminated Unspecified Adult Solid Tumor Protocol Specific National Cancer Institute (NCI) March 2001 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

PKCシグナル伝達経路

相関PKC製品

Tags: Staurosporineを買う | Staurosporine ic50 | Staurosporine供給者 | Staurosporineを購入する | Staurosporine費用 | Staurosporine生産者 | オーダーStaurosporine | Staurosporine化学構造 | Staurosporine分子量 | Staurosporine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID